SCHEMBL12901013

SCHEMBL12901013

O=C(NCCc1ccc(F)cc1)c1sccc1Nc1ccnc2[nH]ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39
TYK2 P29597 2/20 0.39
JAK3 P52333 1/20 0.39
AKT3 Q9Y243 2/20 0.39
TGFBR1 P36897 2/20 0.39
ALDH1A1 P00352 2/20 0.39
NEK1 Q96PY6 1/20 0.38
POLB P06746 2/20 0.38
AKT1 P31749 1/20 0.38
AKT2 P31751 1/20 0.38
SCD O00767 1/20 0.37
EGFR P00533 1/20 0.37
CDK2 P24941 1/20 0.37
HPGD P15428 1/20 0.37
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19390444 0.90 MAPT (0.46) NPC1RAB9ASMN1; SMN2JAK2JAK1
SCHEMBL12900374 0.90 AKT1 (0.39) NPC1RAB9ASMN1; SMN2JAK2JAK1
SCHEMBL19390620 0.90 RAB9A (0.43) NPC1RAB9ASMN1; SMN2JAK2JAK1
SCHEMBL12901006 0.90 HDAC2 (0.40) NPC1RAB9ASMN1; SMN2JAK2JAK1
SCHEMBL12900383 0.90 KDM4E (0.40) JAK2JAK1TYK2AKT3TGFBR1
SCHEMBL12901011 0.89 SNCA (0.41) NPC1JAK2JAK1TYK2AKT3
SCHEMBL12900377 0.89 KMT2A (0.45) SMN1; SMN2ALDH1A1HPGDLMNAMAPT
SCHEMBL16687548 0.87 KMT2A (0.48) AKT3ALDH1A1
SCHEMBL1231761 0.86 TTBK1 (0.48) NPC1RAB9ASMN1; SMN2JAK2JAK1
SCHEMBL12900697 0.86 HDAC2 (0.42) NPC1RAB9ASMN1; SMN2JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC NPC1 1174/4885RAB9A 1480/4885SMN1; SMN2 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.